Evangelisches Klinikum Bethel gGmbH
- Address
- lock Available on a paid plan
Hematology and Blood Cancers
At Evangelisches Klinikum Bethel gGmbH, a major focus is on hematologic malignancies, especially acute lymphoblastic leukemia, acute myeloid leukemia, multiple myeloma, and aggressive lymphomas. The trials are designed to improve survival, reduce relapse risk, and refine treatment choices for both newly diagnosed and relapsed disease.
- Testing more effective treatment strategies for acute lymphoblastic leukemia and relapsed ALL
- Evaluating new approaches for acute myeloid leukemia and high-risk lymphoma
- Studying therapies for multiple myeloma to deepen response and improve long-term control
This research combines oncology, stem cell transplantation, and palliative medicine expertise to support better outcomes for patients with complex blood cancers.
Solid Tumors in Lung, Bladder, and Gastrointestinal Cancer
The site also conducts extensive studies in neoplasms, with strong activity in non-small cell lung cancer, bladder cancer, and gastroesophageal and gastric cancer. These trials are focused on improving treatment effectiveness, comparing new immunotherapy-based combinations, and finding better options for advanced or hard-to-treat disease.
- Assessing new treatments for advanced non-small cell lung cancer
- Exploring novel options for muscle-invasive and metastatic bladder cancer
- Comparing therapies for gastroesophageal junction and gastric cancer
The research reflects a broad effort to improve outcomes in solid tumors using innovative cancer therapies and better treatment combinations.
Pediatric Oncology and Brain Tumors
A significant part of the portfolio is dedicated to pediatric cancer, including medulloblastoma, ependymoma, neuroblastoma, and low-grade glioma. These trials aim to improve cure rates while also reducing long-term treatment burden and preserving quality of life in children and young people.
- Refining treatment for high-risk medulloblastoma and low-risk medulloblastoma
- Studying therapy strategies for ependymoma and low-grade glioma
- Improving risk-adapted care for neuroblastoma and other childhood tumors
These studies highlight the center’s role in pediatric neuro-oncology and in developing more tailored care for younger patients.
Immunotherapy and Targeted Treatment Research
The clinical trial program includes a strong emphasis on immunotherapy and targeted therapy across several cancers. Researchers are evaluating new combinations and comparing them with established treatment options to improve response rates and survival.
- Testing checkpoint inhibitor-based approaches in lung and bladder cancer
- Studying targeted treatments for RAF-altered glioma and TROP2-positive lung cancer
- Exploring novel immune-based strategies for myeloma and lymphoma
This area shows how the site contributes to modern precision oncology by matching treatments more closely to disease biology.
Neurology, Stroke, and Cardiovascular Disease
Beyond cancer, the site is active in cardiovascular diseases and neurologic disorders, including acute ischemic stroke and atrial fibrillation. These studies are aimed at improving recovery, preventing complications, and reducing future cardiovascular risk.
- Evaluating better treatment after acute ischemic stroke
- Studying ways to lower risk in patients with atrial fibrillation
- Assessing interventions that may improve short- and long-term clinical outcomes
The research supports more effective care for patients with urgent vascular and neurological conditions.
Metabolic, Kidney, Skin, and Infection-Related Research
The trial portfolio also covers nutritional and metabolic diseases, kidney injury, skin and connective tissue diseases, and virus diseases. These studies range from prevention to treatment evaluation, with attention to both adult and pediatric patients.
- Investigating care for metabolic acidosis and acute kidney injury
- Studying prevention of atopic dermatitis in children at high risk
- Assessing treatment approaches for viral infection in critically ill patients
This broader research activity at the hospital shows a commitment to improving everyday clinical care across several important non-cancer diseases.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 8 therapeutic areas and 15 of 104 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 96 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 18 by active trials.
lock +17 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB4trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Evangelisches Klinikum Bethel gGmbH
lock Showing 1 of 34 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) with Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL) | Karolinska University Hospital | Phase IV | Recruiting | Jul 2020 | — |
IMP list
lock Showing 1 of 104 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Vincristine Sulfate | 8 | Unknown | 2015-06-02 | 2023-04-19 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.